PMID- 17646666
OWN - NLM
STAT- MEDLINE
DCOM- 20070912
LR  - 20220317
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 25
IP  - 24
DP  - 2007 Aug 20
TI  - Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is 
      prognostically superior to international prognostic score in advanced-stage 
      Hodgkin's lymphoma: a report from a joint Italian-Danish study.
PG  - 3746-52
AB  - PURPOSE: Starting from November 2001, 260 newly diagnosed patients with Hodgkin's 
      lymphoma (HL) were consecutively enrolled in parallel Italian and Danish 
      prospective trials to evaluate the prognostic role of an early interim 
      2-[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and 
      the International Prognostic Score (IPS) in advanced HL, treated with 
      conventional ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) therapy. 
      PATIENTS AND METHODS: Most patients (n = 190) presented with advanced disease 
      (stages IIB through IVB), whereas 70 presented in stage IIA with adverse 
      prognostic factors. All but 11 patients were treated with standard ABVD therapy 
      followed by consolidation radiotherapy in case of bulky presentation or residual 
      tumor mass. Conventional radiologic staging was performed at baseline. FDG-PET 
      scan was performed at baseline and after two courses of ABVD (PET-2). No 
      treatment change was allowed on the basis of the PET-2 results. RESULTS: After a 
      median follow-up of 2.19 years (range, 0.32 to 5.18 years), 205 patients were in 
      continued complete remission and two patients were in partial remission. 
      Forty-three patients progressed during therapy or immediately after, whereas 10 
      patients relapsed. The 2-year progression-free survival for patients with 
      positive PET-2 results was 12.8% and for patients with negative PET-2 results was 
      95.0% (P < .0001). In univariate analysis, the treatment outcome was 
      significantly associated with PET-2 (P < .0001), stage IV (P < .0001), WBC more 
      than 15,000 (P < .0001), lymphopenia (P < .001), IPS as a continuous variable (P 
      < .0001), extranodal involvement (P < .0001), and bulky disease (P = .012). In 
      multivariate analyses, only PET-2 turned out to be significant (P < .0001). 
      CONCLUSION: PET-2 overshadows the prognostic value of IPS and emerges as the 
      single most important tool for planning of risk-adapted treatment in advanced HL.
FAU - Gallamini, Andrea
AU  - Gallamini A
AD  - Department of Hematology, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy. 
      andrea.gallamini@agx.it
FAU - Hutchings, Martin
AU  - Hutchings M
FAU - Rigacci, Luigi
AU  - Rigacci L
FAU - Specht, Lena
AU  - Specht L
FAU - Merli, Francesco
AU  - Merli F
FAU - Hansen, Mads
AU  - Hansen M
FAU - Patti, Caterina
AU  - Patti C
FAU - Loft, Annika
AU  - Loft A
FAU - Di Raimondo, Francesco
AU  - Di Raimondo F
FAU - D'Amore, Francesco
AU  - D'Amore F
FAU - Biggi, Alberto
AU  - Biggi A
FAU - Vitolo, Umberto
AU  - Vitolo U
FAU - Stelitano, Caterina
AU  - Stelitano C
FAU - Sancetta, Rosario
AU  - Sancetta R
FAU - Trentin, Livio
AU  - Trentin L
FAU - Luminari, Stefano
AU  - Luminari S
FAU - Iannitto, Emilio
AU  - Iannitto E
FAU - Viviani, Simonetta
AU  - Viviani S
FAU - Pierri, Ivana
AU  - Pierri I
FAU - Levis, Alessandro
AU  - Levis A
LA  - eng
PT  - Journal Article
DEP - 20070723
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Disease-Free Survival
MH  - Female
MH  - *Fluorodeoxyglucose F18
MH  - Hodgkin Disease/*diagnostic imaging/drug therapy/mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Radionuclide Imaging
MH  - *Radiopharmaceuticals
MH  - Survival Rate
EDAT- 2007/07/25 09:00
MHDA- 2007/09/13 09:00
CRDT- 2007/07/25 09:00
PHST- 2007/07/25 09:00 [pubmed]
PHST- 2007/09/13 09:00 [medline]
PHST- 2007/07/25 09:00 [entrez]
AID - JCO.2007.11.6525 [pii]
AID - 10.1200/JCO.2007.11.6525 [doi]
PST - ppublish
SO  - J Clin Oncol. 2007 Aug 20;25(24):3746-52. doi: 10.1200/JCO.2007.11.6525. Epub 
      2007 Jul 23.